After Hours
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stocks Info
This NASDAQ-listed company operates within the Biotechnology industry segment, falling under the Healthcare sector. The current market capitalization of Vertex Pharmaceuticals, Inc. is $101.82B. A total of 0.7 million shares were traded on the day, compared to an average of 1.27M shares.
In the most recent transaction, Ambrose Kristen sold 240 shares of VRTX for 419.00 per share on Apr 02 ’24. After the transaction, the SVP & Chief Accounting Officer now owns 7,500 company shares. In a previous transaction on Feb 26 ’24, Arbuckle Stuart A sold 5,034 shares at 425.70 per share. VRTX shares that EVP, COO owns now total 49,691.
Among the insiders who sold shares, ALTSHULER DAVID disposed of 4,239 shares on Feb 26 ’24 at a per-share price of $425.70. This resulted in the EVP, Global Research and CSO holding 25,813 shares of VRTX after the transaction. In another insider transaction, Sachdev Amit sold 3,004 shares at $425.70 per share on Feb 26 ’24. Company shares held by the EVP Chief Patient & Ext Af Off now total 55,325.
Even though price targets are rarely accurate, they do tend to exert some kind of influence from time to time and are often considered important by markets. In terms of 52-week highs and lows, VRTX has a high of $448.40 and a low of $316.43.
As of this writing, VRTX has an earnings estimate of $Viking Therapeutics, Inc. per share for the current quarter. EPS was calculated based on a consensus of RTX Corporation estimates, with a high estimate of $Vertiv Holdings, LLC per share and a lower estimate of $Vertex Pharmaceuticals Incorpor.
Balance Sheet Annually/Quarterly
In a balance sheet, you can see what assets and liabilities the company has, as well as how much equity investors have invested. These figures can be used to calculate a company’s financial ratios to give investors a better idea of its prospects. VRTX’s latest balance sheet shows that the firm has $7.52B in Cash & Short Term Investments as of fiscal 2021. There were $967.40M in debt and $2.14B in liabilities at the time. Its Book Value Per Share was $68.22, while its Total Shareholder’s Equity was $10.10B.
Analysts Opinion
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for VRTX is Buy with a score of 4.13.
